NYSE: RMDResmed Inc Stock
$228.12+3.40 (+1.51%)
Updated Apr 17, 2026
RMD Price
$228.12
Fair Value Price
N/A
Market Cap
$33.23B
52 Week Low
$209.31
52 Week High
$293.81
P/E
22.47x
P/B
5.26x
P/S
6.51x
PEG
2.37x
Dividend Yield
1.02%
Revenue
$5.40B
Earnings
$1.49B
Gross Margin
60.9%
Operating Margin
33.34%
Profit Margin
27.5%
Debt to Equity
0.35
Operating Cash Flow
$2B
Beta
0.81
Next Earnings
Apr 23, 2026
Ex-Dividend
N/A
Next Dividend
N/A
RMD Overview
ResMed Inc. manufactures medical equipment for the diagnosis, treatment and management of sleep-disordered breathing, sleep apnea, and chronic obstructive pulmonary disease. Offerings include continuous positive airway pressure devices, auto-bilevel devices, variable positive airway pressure devices, automatic positive airway pressure devices, humidifiers, ventilation products, masks, headgear, and data/patient management products. The comany serves sleep clinics, home healthcare dealers, and third party payers. ResMed was founded in 1989 and is headquartered in San Diego, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine RMD's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
B
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical
Industry Rating
B
RMD
Ranked#16 of 40
Ranked#16 of 40
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $10.58 | A | |
| $9.78 | A | |
| $27.84 | A |
Be the first to know about important RMD news, forecast changes, insider trades & much more!
RMD News
Overview
Due Diligence Score
–
Industry Average (31)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how RMD scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RMD ($228.12) is trading above its intrinsic value of $90.21, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
RMD is good value based on its earnings relative to its share price (22.47x), compared to the US market average (31.07x)
P/E vs Market Valuation
RMD is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more RMD due diligence checks available for Premium users.
Valuation
RMD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
22.47x
Industry
-563.96x
Market
31.07x
RMD is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
RMD is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
RMD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.26x
Industry
3.55x
RMD is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
RMD price to earnings growth (PEG)
For valuing profitable companies with growth potential
RMD is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
RMD's financial health
Profit margin
Revenue
$1.4B
Net Income
$392.6M
Profit Margin
27.6%
RMD's Earnings (EBIT) of $1.80B... subscribe to Premium to read more.
Interest Coverage Financials
RMD's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$8.5B
Liabilities
$2.2B
Debt to equity
0.35
RMD's short-term assets ($3.82B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RMD's short-term assets ($3.82B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RMD's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
RMD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$339.7M
Investing
-$50.9M
Financing
-$258.3M
RMD's operating cash flow ($1.91B)... subscribe to Premium to read more.
Debt Coverage Financials
RMD vs Medical Stocks
Resmed Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.